drugset / Trial / NCT02692677

A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

NCT02692677

Phase 1 Completed 8 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to assess the absorption, metabolism, and excretion of JNJ-42756493 in healthy male adult participants after administration of a single oral dose of 12 milligram (mg) of unlabeled JNJ-42756493 admixed with 14C JNJ-42756493.

Timeline

Start
2016-03
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Erdafitinib Small molecule 12 mg Oral

Indications

No indication recorded.